Could a simple sugar ease Crohn's? new trial aims to find out

NCT ID NCT07225998

Not yet recruiting Disease control Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether an oral supplement called N-acetylglucosamine (GlcNAc) can safely help control Crohn's disease in the ileum or ileocolon. Forty adults with stable Crohn's will receive either GlcNAc or a placebo for 6 weeks, then switch after a washout period. The study focuses on safety and symptom changes, and includes people with and without a specific genetic variant linked to the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: N-acetylglucosamine (GlcNAc)
What this could lead to: If it works, this could point toward a new treatment option for Crohn's disease, especially for patients with a specific genetic mutation.
What could go wrong: This is a small, early-phase proof-of-concept study. It may not show clear benefit, and results may not apply to all Crohn's patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHNS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHNS DISEASE

Contacts and locations

Locations

Johns Hopkins University School of Medicine

Baltimore, Maryland, 21205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.